289 related articles for article (PubMed ID: 28763686)
1. In silico molecular docking studies of new potential 4-phthalazinyl-hydrazones on selected Trypanosoma cruzi and Leishmania enzyme targets.
Romero AH; López SE
J Mol Graph Model; 2017 Sep; 76():313-329. PubMed ID: 28763686
[TBL] [Abstract][Full Text] [Related]
2. Computational and Investigative Study of Flavonoids Active Against Typanosoma cruzi and Leishmania spp.
Ribeiro FF; Junior FJ; da Silva MS; Scotti MT; Scotti L
Nat Prod Commun; 2015 Jun; 10(6):917-20. PubMed ID: 26197515
[TBL] [Abstract][Full Text] [Related]
3. Febrifugine analogues as Leishmania donovani trypanothione reductase inhibitors: binding energy analysis assisted by molecular docking, ADMET and molecular dynamics simulation.
Pandey RK; Kumbhar BV; Srivastava S; Malik R; Sundar S; Kunwar A; Prajapati VK
J Biomol Struct Dyn; 2017 Jan; 35(1):141-158. PubMed ID: 27043972
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, structure-activity relationship and mechanism of action studies of a series of 4-chloro-1-phthalazinyl hydrazones as a potent agent against Leishmania braziliensis.
Romero AH; Medina R; Alcala A; García-Marchan Y; Núñez-Duran J; Leañez J; Mijoba A; Ciangherotti C; Serrano-Martín X; López SE
Eur J Med Chem; 2017 Feb; 127():606-620. PubMed ID: 28119201
[TBL] [Abstract][Full Text] [Related]
5. Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs.
Chan C; Yin H; Garforth J; McKie JH; Jaouhari R; Speers P; Douglas KT; Rock PJ; Yardley V; Croft SL; Fairlamb AH
J Med Chem; 1998 Jan; 41(2):148-56. PubMed ID: 9457238
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and molecular modelling studies of phenyl linked oxadiazole-phenylhydrazone hybrids as potent antileishmanial agents.
Taha M; Ismail NH; Imran S; Anouar EH; Selvaraj M; Jamil W; Ali M; Kashif SM; Rahim F; Khan KM; Adenan MI
Eur J Med Chem; 2017 Jan; 126():1021-1033. PubMed ID: 28012342
[TBL] [Abstract][Full Text] [Related]
7. Metal-based compounds as prospective antileishmanial agents: inhibition of trypanothione reductase by selected gold complexes.
Colotti G; Ilari A; Fiorillo A; Baiocco P; Cinellu MA; Maiore L; Scaletti F; Gabbiani C; Messori L
ChemMedChem; 2013 Oct; 8(10):1634-7. PubMed ID: 24039168
[TBL] [Abstract][Full Text] [Related]
8. Insights about resveratrol analogs against trypanothione reductase of
da Silva AD; Dos Santos JA; Machado PA; Alves LA; Laque LC; de Souza VC; Coimbra ES; Capriles PVSZ
J Biomol Struct Dyn; 2019 Jul; 37(11):2960-2969. PubMed ID: 30058445
[TBL] [Abstract][Full Text] [Related]
9. Structure-based virtual screening, molecular docking, ADMET and molecular simulations to develop benzoxaborole analogs as potential inhibitor against Leishmania donovani trypanothione reductase.
Pandey RK; Kumbhar BV; Sundar S; Kunwar A; Prajapati VK
J Recept Signal Transduct Res; 2017 Feb; 37(1):60-70. PubMed ID: 27147242
[TBL] [Abstract][Full Text] [Related]
10. Developing imidazole analogues as potential inhibitor for Leishmania donovani trypanothione reductase: virtual screening, molecular docking, dynamics and ADMET approach.
Pandey RK; Sharma D; Bhatt TK; Sundar S; Prajapati VK
J Biomol Struct Dyn; 2015; 33(12):2541-53. PubMed ID: 26305585
[TBL] [Abstract][Full Text] [Related]
11. Molecular Docking and Binding Mode Analysis of Plant Alkaloids as in vitro and in silico Inhibitors of Trypanothione Reductase from Trypanosoma cruzi.
Argüelles AJ; Cordell GA; Maruenda H
Nat Prod Commun; 2016 Jan; 11(1):57-62. PubMed ID: 26996020
[TBL] [Abstract][Full Text] [Related]
12. Aryl- or heteroaryl-based hydrazinylphthalazine derivatives as new potential antitrypanosomal agents.
Romero AH; Rodríguez J; García-Marchan Y; Leañez J; Serrano-Martín X; López SE
Bioorg Chem; 2017 Jun; 72():51-56. PubMed ID: 28359970
[TBL] [Abstract][Full Text] [Related]
13.
Matadamas-Martínez F; Hernández-Campos A; Téllez-Valencia A; Vázquez-Raygoza A; Comparán-Alarcón S; Yépez-Mulia L; Castillo R
Molecules; 2019 Sep; 24(18):. PubMed ID: 31487860
[TBL] [Abstract][Full Text] [Related]
14. Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development.
Cavazzuti A; Paglietti G; Hunter WN; Gamarro F; Piras S; Loriga M; Allecca S; Corona P; McLuskey K; Tulloch L; Gibellini F; Ferrari S; Costi MP
Proc Natl Acad Sci U S A; 2008 Feb; 105(5):1448-53. PubMed ID: 18245389
[TBL] [Abstract][Full Text] [Related]
15. First example of peptides targeting the dimer interface of Leishmania infantum trypanothione reductase with potent in vitro antileishmanial activity
Ruiz-Santaquiteria M; Sánchez-Murcia PA; Toro MA; de Lucio H; Gutiérrez KJ; de Castro S; Carneiro FAC; Gago F; Jiménez-Ruiz A; Camarasa MJ; Velázquez S
Eur J Med Chem; 2017 Jul; 135():49-59. PubMed ID: 28431354
[TBL] [Abstract][Full Text] [Related]
16. Molecular docking, structure-activity relationship and biological evaluation of the anticancer drug monastrol as a pteridine reductase inhibitor in a clinical isolate of Leishmania donovani.
Kaur J; Sundar S; Singh N
J Antimicrob Chemother; 2010 Aug; 65(8):1742-8. PubMed ID: 20519355
[TBL] [Abstract][Full Text] [Related]
17. Investigation of trypanothione reductase inhibitory activity by 1,3,4-thiadiazolium-2-aminide derivatives and molecular docking studies.
Rodrigues RF; Castro-Pinto D; Echevarria A; dos Reis CM; Del Cistia CN; Sant'Anna CM; Teixeira F; Castro H; Canto-Cavalheiro M; Leon LL; Tomás A
Bioorg Med Chem; 2012 Mar; 20(5):1760-6. PubMed ID: 22304847
[TBL] [Abstract][Full Text] [Related]
18. Studies of 4-arylthiazolylhydrazones derived from 1-indanones as Trypanosoma cruzi squalene epoxidase inhibitors by molecular simulations.
Noguera GJ; Fabian LE; Lombardo E; Finkielsztein LM
Org Biomol Chem; 2018 Nov; 16(44):8525-8536. PubMed ID: 30357228
[TBL] [Abstract][Full Text] [Related]
19. Binding to large enzyme pockets: small-molecule inhibitors of trypanothione reductase.
Persch E; Bryson S; Todoroff NK; Eberle C; Thelemann J; Dirdjaja N; Kaiser M; Weber M; Derbani H; Brun R; Schneider G; Pai EF; Krauth-Siegel RL; Diederich F
ChemMedChem; 2014 Aug; 9(8):1880-91. PubMed ID: 24788386
[TBL] [Abstract][Full Text] [Related]
20. Trypanothione Reductase and Superoxide Dismutase as Current Drug Targets for Trypanosoma cruzi: An Overview of Compounds with Activity against Chagas Disease.
Beltran-Hortelano I; Perez-Silanes S; Galiano S
Curr Med Chem; 2017 May; 24(11):1066-1138. PubMed ID: 28025938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
